🦴 Hypercalcemia Management
This tool guides hypercalcemia management by calcium level, symptoms, and renal function, framing fluids, antiresorptives (bisphosphonate/denosumab), calcitonin, and special-etiology therapy.
Never give a loop diuretic before adequate fluid resuscitation — it worsens calcium handling; reserve it for volume overload after rehydration. (original synthesis · not guideline verbatim)
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
When to use
Use to scale treatment: mild asymptomatic disease is managed by cause and precipitant avoidance, while moderate-severe or symptomatic hypercalcemia gets IV saline first-line plus antiresorptive and rapid calcitonin.
How it works
Mild asymptomatic → treat cause/avoid precipitants. Moderate-severe/symptomatic → IV normal saline (urine output ≥ 100 mL/h, loop diuretic only after fluids) + zoledronic acid (or denosumab if renal impairment) + calcitonin for rapid lowering.
Key points
- Never give a loop diuretic before adequate fluid resuscitation — it worsens calcium handling; reserve it for volume overload after rehydration. (original synthesis · not guideline verbatim)
- Denosumab is preferred when renal impairment or a bisphosphonate contraindication is present, and for refractory/recurrent cases.
- Calcitriol-mediated hypercalcemia (vitamin D toxicity, granulomatous disease, lymphoma) responds to glucocorticoids.
References
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Calcium level | Mild (< 3.0 mmol/L / < 12 mg/dL) |
|---|---|
| Symptoms | Symptomatic |
| Renal impairment or bisphosphonate contraindication | No |
→DispositionModerate/symptomatic: aggressive calcium-lowering
- First-line fluids:IV normal saline to correct dehydration and promote urinary calcium excretion (target urine output ≥ 100 mL/h); after adequate fluids, add loop diuretic (furosemide) for those at risk of volume overload (heart failure/renal impairment) — never give a loop diuretic before fluids
- Inhibit bone resorption:IV bisphosphonate: zoledronic acid 4 mg infused over ≥ 15 min (superior to pamidronate; onset 2–4 days); switch to denosumab in renal impairment
- Rapid short-term:Calcitonin 100 IU q6–8h SC/IM is rapid but short-acting; for severe (> 3.5 mmol/L / > 14 mg/dL) combine with a bisphosphonate or denosumab
| Calcium level | Severe (> 3.5 mmol/L / > 14 mg/dL) |
|---|---|
| Symptoms | Asymptomatic |
| Renal impairment or bisphosphonate contraindication | Yes |
→DispositionSevere: urgent combined calcium-lowering
- First-line fluids:IV normal saline to correct dehydration and promote urinary calcium excretion (target urine output ≥ 100 mL/h); after adequate fluids, add loop diuretic (furosemide) for those at risk of volume overload (heart failure/renal impairment) — never give a loop diuretic before fluids
- Inhibit bone resorption:Denosumab (not renally cleared, suitable for renal impairment or bisphosphonate contraindication; also for refractory/recurrent)
- Rapid short-term:Calcitonin 100 IU q6–8h SC/IM is rapid but short-acting; for severe (> 3.5 mmol/L / > 14 mg/dL) combine with a bisphosphonate or denosumab
Frequently asked questions
- What is Hypercalcemia Management?
- This tool guides hypercalcemia management by calcium level, symptoms, and renal function, framing fluids, antiresorptives (bisphosphonate/denosumab), calcitonin, and special-etiology therapy.
- How is Hypercalcemia Management calculated? What is the core formula?
- Mild asymptomatic → treat cause/avoid precipitants. Moderate-severe/symptomatic → IV normal saline (urine output ≥ 100 mL/h, loop diuretic only after fluids) + zoledronic acid (or denosumab if renal impairment) + calcitonin for rapid lowering.
- When is Hypercalcemia Management used?
- Use to scale treatment: mild asymptomatic disease is managed by cause and precipitant avoidance, while moderate-severe or symptomatic hypercalcemia gets IV saline first-line plus antiresorptive and rapid calcitonin.
- What are the key clinical points for Hypercalcemia Management?
- Never give a loop diuretic before adequate fluid resuscitation — it worsens calcium handling; reserve it for volume overload after rehydration. (original synthesis · not guideline verbatim) Denosumab is preferred when renal impairment or a bisphosphonate contraindication is present, and for refractory/recurrent cases. Calcitriol-mediated hypercalcemia (vitamin D toxicity, granulomatous disease, lymphoma) responds to glucocorticoids.
- What are the limits and cautions when using Hypercalcemia Management?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- How is Hypercalcemia Management calculated in practice? Can you show a worked example?
- Inputs: Calcium level Mild (< 3.0 mmol/L / < 12 mg/dL), Symptoms Symptomatic, Renal impairment or bisphosphonate contraindication No → Result: Disposition Moderate/symptomatic: aggressive calcium-lowering(First-line fluids: IV normal saline to correct dehydration and promote urinary calcium excretion (target urine output ≥ 100 mL/h); after adequate fluids, add loop diuretic (furosemide) for those at risk of volume overload (heart failure/renal impairment) — never give a loop diuretic before fluids, Inhibit bone resorption: IV bisphosphonate: zoledronic acid 4 mg infused over ≥ 15 min (superior to pamidronate; onset 2–4 days); switch to denosumab in renal impairment, Rapid short-term: Calcitonin 100 IU q6–8h SC/IM is rapid but short-acting; for severe (> 3.5 mmol/L / > 14 mg/dL) combine with a bisphosphonate or denosumab) Inputs: Calcium level Severe (> 3.5 mmol/L / > 14 mg/dL), Symptoms Asymptomatic, Renal impairment or bisphosphonate contraindication Yes → Result: Disposition Severe: urgent combined calcium-lowering(First-line fluids: IV normal saline to correct dehydration and promote urinary calcium excretion (target urine output ≥ 100 mL/h); after adequate fluids, add loop diuretic (furosemide) for those at risk of volume overload (heart failure/renal impairment) — never give a loop diuretic before fluids, Inhibit bone resorption: Denosumab (not renally cleared, suitable for renal impairment or bisphosphonate contraindication; also for refractory/recurrent), Rapid short-term: Calcitonin 100 IU q6–8h SC/IM is rapid but short-acting; for severe (> 3.5 mmol/L / > 14 mg/dL) combine with a bisphosphonate or denosumab)